Qian Wu

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).

C. Bloomfield, H. Deeg, K. Mrózek, 2021, Blood advances.

Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216

P. Harari, Q. Zhang, D. Rosenthal, 2018, Head & neck.

Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors

A. Plückthun, S. Riddell, M. Jensen, 2019, Clinical Cancer Research.

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

Chongrui Xu, Xuchao Zhang, Qian Wu, 2022, JTO clinical and research reports.

Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer

Christopher I. Li, V. Gadi, D. Doody, 2022, Annals of Surgical Oncology.

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

L. Chow, C. Baik, K. Eaton, 2019, Clinical Cancer Research.

Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy

R. Lynch, M. Shadman, R. Cassaday, 2020, British journal of haematology.